Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.

BACKGROUND Trivalent live attenuated influenza vaccine (LAIV3) was licensed and recommended for use in 2003 in children and adults 2-49 years of age. Post-licensure safety data have been limited, particularly in adults. METHODS We searched Vaccine Adverse Event Reporting System (VAERS) for US reports after LAIV3 from July 1, 2005-June 30, 2013 (eight influenza seasons) in adults aged ≥ 18 years old. We conducted descriptive analyses and clinically reviewed serious reports (i.e., death, life-threatening illness, hospitalization, prolonged hospitalization, or permanent disability) and reports of selected conditions of interest. We used empirical Bayesian data mining to identify adverse events (AEs) that were reported more frequently than expected. We calculated crude AE reporting rates to VAERS by influenza season. RESULTS During the study period, VAERS received 1207 LAIV3 reports in adults aged 18-49 years old; 107 (8.9%) were serious, including four death reports. The most commonly reported events were expired drug administered (n=207, 17%), headache (n=192, 16%), and fever (n=133, 11%). The most common diagnostic categories for non-fatal serious reports were neurological (n=40, 39%), cardiovascular (n=14, 14%), and other non-infectious conditions (n=20, 19%). We noted a higher proportion of Guillain-Barré syndrome (GBS) and cardiovascular reports in the Department of Defense (DoD) population compared to the civilian population. Data mining detected disproportional reporting of ataxia (n=15); clinical review revealed that ataxia was a component of diverse clinical entities including GBS. CONCLUSIONS Review of VAERS reports are reassuring, the only unexpected safety concern for LAIV3 identified was a higher than expected number of GBS reports in the DoD population, which is being investigated. Reports of administration of expired LAIV3 represent administration errors and indicate the need for education, training and screening regarding the approved indications.

[1]  James Singleton,et al.  Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. , 2010, Vaccine.

[2]  J. Atwood,et al.  Myopericarditis following smallpox vaccination. , 2004, American journal of epidemiology.

[3]  E. Clayton,et al.  Adverse Effects of Vaccines , 2011 .

[4]  R. O’Neill,et al.  Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA’s Spontaneous Reports Database , 2002, Drug safety.

[5]  Andrea Sutherland,et al.  Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009. , 2011, American journal of obstetrics and gynecology.

[6]  Robert Ball,et al.  Adverse events reported following live, cold-adapted, intranasal influenza vaccine. , 2005, JAMA.

[7]  J. Falloon,et al.  randomized , double-blind noninferiority study of quadrivalent live attenuated nfluenza vaccine in adults , 2011 .

[8]  William DuMouchel,et al.  Empirical bayes screening for multi-item associations , 2001, KDD '01.

[9]  Robert T. Chen,et al.  Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. , 2004, The Pediatric infectious disease journal.

[10]  J. Falloon,et al.  Quadrivalent Ann Arbor strain live-attenuated influenza vaccine , 2012, Expert review of vaccines.

[11]  X. Wu,et al.  A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18-49 years of age. , 2012, Vaccine.

[12]  D. Swerdlow,et al.  Myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination among civilians in the United States, January-October 2003. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  D. Tribble,et al.  The epidemiology of Guillain-Barré Syndrome in U.S. military personnel: a case-control study , 2009, BMC Research Notes.

[14]  N. Cox,et al.  Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2009 .

[15]  Elaine L. Baker.  Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) , 2009 .

[16]  Robert T. Chen,et al.  Morbidity and Mortality Weekly Report , 2002 .

[17]  Matthew Wise,et al.  Population Incidence of Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis , 2011, Neuroepidemiology.

[18]  X. Wu,et al.  The safety and effectiveness of self-administration of intranasal live attenuated influenza vaccine in adults. , 2013, Vaccine.

[19]  C. Bridges,et al.  Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2003, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[20]  J A Bryan,et al.  Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. , 1979, American journal of epidemiology.

[21]  R. Harpaz,et al.  Prevention of plague: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 1996, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[22]  J. Sejvar,et al.  Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. , 2011, Vaccine.

[23]  M. Pemberton,et al.  Military healthcare providers reporting of adverse events following immunizations to the vaccine adverse event reporting system. , 2014, Military medicine.

[24]  J. Kaldor,et al.  Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[25]  N. Cox,et al.  Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[26]  Jan Bonhoeffer,et al.  Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. , 2007, Vaccine.